ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

FLGT Fulgent Genetics Inc

21.32
0.00 (0.00%)
Pre Market
Last Updated: 12:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Fulgent Genetics Inc NASDAQ:FLGT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 21.32 21.25 21.50 12 12:00:00

Fulgent Genetics to Announce Second Quarter 2020 Financial Results on Tuesday August 4, 2020

14/07/2020 1:00pm

GlobeNewswire Inc.


Fulgent Genetics (NASDAQ:FLGT)
Historical Stock Chart


From May 2019 to May 2024

Click Here for more Fulgent Genetics Charts.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its second quarter 2020 financial results after the market closes on Tuesday August 4, 2020. The company’s Chairman and Chief Executive Officer Ming Hsieh, Chief Financial Officer Paul Kim and Chief Commercial Officer Brandon Perthuis will host a conference call for the investment community the same day at 4:30 PM ET (1:30 PM PT) to discuss the results and answer questions.

The call can be accessed through a live audio webcast in the Investors section of the company’s website, http://ir.fulgentgenetics.com, and through a live conference call by dialing (855) 321-9535 using the conference ID 2797888. An audio replay will be available in the Investors section of the company’s website or by calling (855) 859-2056 using passcode 2797888 through August 11, 2020.

About Fulgent Genetics

Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.

Investor Relations Contacts:The Blueshirt GroupMelanie Solomon, 415-217-4964, melanie@blueshirtgroup.com

1 Year Fulgent Genetics Chart

1 Year Fulgent Genetics Chart

1 Month Fulgent Genetics Chart

1 Month Fulgent Genetics Chart

Your Recent History

Delayed Upgrade Clock